ABSTRACT
Context: Research interest in monoamine oxidase (MAO) as a promising drug target for neurodegenerative diseases has a long history. However, efforts to develop MAO inhibitors (MAOIs) from marine sources have been limited, despite the increasing number of interesting marine natural products.
Objective: To review the potential of marine natural products as MAOIs source, including their activities and selectivity on MAO.
Methods: Public databases such as SciFinder, MarinLit and PubMed were systematically searched from 1991 until Dec 2019. MAO and MAOI were the key terms searched combined with marine natural products and marine.
Results: Six classes of marine natural products with good selectivity between the two MAO subtypes were organized with their selectivity and sources.
Conclusions: This is the first review to investigate the potential of marine natural products as MAOIs source. Despite the small number of known MAOIs from marine sources, marine natural products are potential leads for the further development of MAOI drugs with novel chemical frames and good selectivity.

Introduction
Monoamine oxidases (MAOs, E.C. 1.4.3.4) are members of the flavin-containing amine oxidoreductases which catalyze the oxidative deamination (Al-Nuaimi et al. 2012). In humans, these ubiquitous mitochondrial enzymes have been categorized into two subtypes, MAO-A and MAO-B. Both subtypes are found in neurons and astroglia, and are distributed unevenly outside the central nervous system (Shih and Chen 2004). Each isoform has preferred substrates, stemming from structural differences in the entrance cavity, hydrophobicity of the cavities, and amino acids that are responsible for binding. There are several classes of MAOI drugs on the market based on reversibility and selectivity (Shulman et al. 2013; Entzeroth and Ratty 2017). Reversibility means the way of the inhibitor binding into the enzyme whether covalently or non-covalently. Selectivity is a preference for one of the MAO subtypes. Non-selective and irreversible MAOI such as isocarboxazid, phenelzine and tranylcypromine were approved to treat depression in the US (Shulman et al. 2013). Selective MAO-A inhibitors with reversibility such as brofaromin and moclobemide were employed to treat social anxiety disorder (Entzeroth and Ratty 2017). However, the results were contradictory that these were not approved in the US. Irreversible MAO-B inhibitors, selegiline and rasagiline, were used to treat the symptoms of Parkinson’s disease (Dezsi and Vecsei 2017). At present, the development of reversible, specific and safe MAOIs is required.
Previously, the search for novel MAOIs has mainly focussed on herbal sources (Erdogan Orhan 2016). Microbial sources were also extensively studied, such as in the case of pimprinines, trans-cinnamic acid amid and phenethylamine (Takeuchi et al. 1973). However, there are only four papers reporting on marine MAOIs which have been published since 1973 (Lee et al. 1999; Lee et al. 2015; Lee, Choi, et al. 2017; Lee, Kim, et al. 2017), and these are mostly focussed on *Streptomyces* as a source.

Additionally, the interest in marine natural products in relation to this subject has been limited. Considering the increasing number of marine natural products, only a handful of MAOIs have been reported so far. In this review, we describe the various MAOIs of marine origin (Table 1). For the purpose of this review, synthetic analogs were indicated with the letter attached to the mother natural product number.

**Discussion**

**Aplysinopsins**

Aplysinopsins have been isolated from various classes of marine organisms such as molluscs, corals, sea anemones and particularly from marine sponges. Aplysinopsin was reported for the first time in 1977 from Australian sponges belonging to the genus *Thorecta*, which has been re-assigned as *Aplysinospin* (Kazlauskas et al. 1977). Aplysinopsins are tryptophan-derived indole-bearing natural products with a modified functional group within. Over two dozen alysinsopsins have been reported from marine organisms, with a wide range of bioactivities including antimicrobial, antimalarial and antitumor activity (Bialonska and Zjawiony 2009).

Among them, methylaplysinopsin (1, Figure 1) has shown potent in vivo antidepressant activity, and was later shown to have reversible inhibitory activity against MAO (Baird-Lambert et al. 1982). Detailed pharmacokinetic studies followed this study, which showed the drug-like property of 1. Successive studies developed synthetic analogs as MAOIs with improved IC₅₀ values down to 5 nM against MAO-A (Aoki et al. 2001; Segraves and Crews 2005). These studies, covering 50 synthetic analogs, improved not only the activities but also selectivity in discriminating between the two isoforms of MAO. Some of the most potent alysinspin synthetic analogs are shown in Figure 1. It is interesting that the addition of a bromine atom in the indole ring system results in a dramatic increase in the activity.

**Piloquinones**

Piloquine (2, Figure 2) was reported in 1963 from the mycelium of *Streptomyces pilosus* (Connor et al. 1963). However, the inhibitory activities of 2 on recombinant human MAO were not studied until five decades later, with a derivative (3) from *Streptomyces* sp. CNQ-027 (Lee, Choi, et al. 2017). Interestingly, both piloquinones showed MAO-B selectivity over MAO-A, with a good selective index value of 0.19 (2, MAO-B IC₅₀ 1.21 μM), or no MAO-A inhibitory activity up to 80 μM (3, MAO-B IC₅₀ 14.5 μM). This finding was in conflict with a previous study which showed MAO-A selectivity with a dibenzopyrone frame fungal secondary metabolite (Lee, Kim, et al. 2017). The attached pentyl chain may be responsible for the selective conversion of piloquinones. Compound 3 showed potent inhibitory activity comparable with current Parkinson’s disease drugs, based on a MAO-B inhibitory mechanism. It is noteworthy that 3 is the most potent MAO-B inhibitor derived from microbial sources.

**Table 1.** List of marine natural products used as monoamine oxidase (MAO) inhibitors.

| Compounds         | Source                  | Potency (compound number, SI<sup>a</sup>)                      | Reference                                                                 |
|-------------------|-------------------------|-----------------------------------------------------------------|--------------------------------------------------------------------------|
| Aplysinopsins     | Sponge (*Aplysinopsins* sp.) | MAO-A IC₅₀ = 0.0056 μM (1a, 80.2) MAO-A IC₅₀ = 0.035 μM (1c, 290.3) | (Baird-Lambert et al. 1982; Aoki et al. 2001; Segraves and Crews, 2005) |
| Piloquinones      | synthetic analogs       | MAO-B IC₅₀ = 1.21 μM (2, 0.19) MAO-B IC₅₀ = 14.5 μM (3, NA<sup>b</sup>) | (Lee, Choi, et al. 2017)                                                 |
| Anithiactins      | Bacteria (*Streptomyces* sp.) | MAO-A IC₅₀ = 13.0 μM (4, 14.1) MAO-A IC₅₀ = 24 μM (7a, 15.9) MAO-A IC₅₀ = 2.1 μM (7b, 0.08) | (Lee et al. 2015)                                                        |
| Bromopyrroles     | Sponge synthetic analogs | MAO-B IC₅₀ = 2.4 μM (7a, 15.9) MAO-B IC₅₀ = 2.1 μM (7b, 0.08)     | (Rane, Sahu, et al. 2014; Rane, Napahde, et al. 2014)                     |
| Caulerpins        | Algae synthetic analogs | In *s*ilico prediction at high dose (9, NB<sup>b</sup>)           | (Lorenzo et al. 2015)                                                    |
| Astaxanthin       | Algae Shrimps           | MAO-A inhibitory activity at high dose (9, NB<sup>b</sup>)         | (Safarova et al. 2016; Jiang et al. 2017)                                 |

<sup>a</sup>SI stands for ‘selectivity index’, defined by the ratio of IC₅₀ (MAO-B)/IC₅₀ (MAO-A).

<sup>b</sup>NA/NB stands for ‘no inhibition on MAO-A/MAO-B’.

**Figure 1.** MAO inhibiting alysinspins.

**Figure 2.** MAO inhibiting piloquinones.
**Anithiactins**

Anithiactins (4–6, Figure 3) were the first reported aniline bearing 2-phenylthiazole natural products in the class. Initially, moderate acetylcholine esterase (AChE) inhibitory activity of anithiactins was reported, with IC\textsubscript{50} values of 63, 53, and 58 M, respectively, and without cytotoxicity up to 100 M (Kim et al. 2014). Anithiactin A (4) showed moderate inhibitory activity for MAO-A with a selectivity index of 14.1 over MAO-B (Lee et al. 2015). The absence of a methyl ester functional group attached to the thiazole ring resulted in dramatic activity differences among anithiactins (Figure 3). The substitution of the methyl ester with an amine resulted in the complete loss of MAO-B activity of anithiactin B (5), whereas the presence of a carboxylic acid group resulted in IC\textsubscript{50} value of over 170 M for anithiactin C (6) against MAOs. Anithiactin A (4, MAO-A IC\textsubscript{50} 13.0 M) showed a reversible MAO-A inhibitory activity with selectivity over MAO-B, and showed moderate AChE inhibitory activity.

**Bromopyrroles**

Bromopyrroles are marine alkaloids exclusive to sponge with a wide range of bio-activities, such as antibacterial, antifungal, antimalarial, anticoagulant, antiprotozoal, antiviral, antihistaminic, anticancer and anti-inflammatory activities (Rane, Sahu, et al. 2014). Among them, synthetic analogs based on oroidin (7, Figure 4) have been prepared to improve the affinity and selectivity for MAOs (Rane, Napahde, et al. 2014). In vivo mouse experiments have been performed to demonstrate the drug-like properties of these analogs with promising pharmacological activities. The 4,5-dibromopyrrole carboxamide frame of oroidin (7) was retained in these analogs. It is interesting that the substitution of a fluorine atom in compound 7a to a chlorine in 7b dramatically changes the MAO selectivity, with the selectivity index altered from 0.06 (7a, MAO-A IC\textsubscript{50} 2.4 M) to 12.80 (7b, MAO-B IC\textsubscript{50} 2.1 M). The presence of an N-methyl group at the pyrrole ring was one of the favoured features for in vivo mouse antidepressant activity.

**Caulerpins**

Caulerpin (8, Figure 5) has shown calcium channel inhibitory activity (Cavalcante-Silva et al. 2013), with antinociceptive and anti-inflammatory activity (De Souza et al. 2009). Through computer-aided drug design, nine caulerpin analogs have been suggested as potential MAO-B inhibitors from among 108 entities (Lorenzo et al. 2015). In this study, three-dimensional structures were built on the Volsurf descriptors and drug-like scores were calculated using DRAGON software. These virtual screened analogs showed more similarity to Moldock energy than caulerpin.

---

**Figure 3.** MAO inhibiting anithiactins.

**Figure 4.** MAO inhibiting bromopyrroles.

**Figure 5.** MAO inhibiting caulerpins.
(8), with improved drug-like scores. However, experimental validation is needed for validation of the in silico results.

Astaxanthin

Astaxanthin (Figure 6) is a well-known xanthophyll terpenoid that has a wide range of food industry applications as a colouring agent. This lipophilic pigment is responsible for the red colour of marine organisms such as shrimp and algae. The in vivo antidepressant effects of 9 have been studied in the mice, along with its MAO inhibitory effects (Jiang et al. 2017). Furthermore, the molecular binding of 9 with MAO-A and -B enzyme has been studied in silico and compared with the known MAOIs isatin, and lazabemide (Safarova et al. 2016). It is interesting that compound 9 showed a protective effect against cognitive dysfunction in the mouse model (Feng et al. 2018). However, evidence of 9 as an MAOI is limited and requires additional proof.

Conclusions

In this review, several marine natural products with MAO inhibitory activities were discussed, which possess chemical framework such as indole-imidazole, dibromo-pyrrole, naphthoquinone, phenylthiazole, bisindole and xanthophyll. This tendency is consistent with previously reported MAOIs from other sources (Bolasco et al. 2010; Erdogan Orhan 2016). Producers of these MAOIs have a nitrogen-containing quinone, phenylthiazole, bisindole and xanthophyll. It is interesting that most of these MAOIs have a heterocyclic ring system or quinone moiety. This tendency is consistent with previously reported MAOIs from other sources (Bolasco et al. 2010; Erdogan Orhan 2016). Producers of these MAOIs include sponges, algae and marine Streptomyces (Table 1). The most potent MAO-A activity was observed with the alypsinosin analog (1a). Interestingly, most of these marine origin inhibitors show good selectivity between the two MAO subtypes. Aplysinopsin analog (1c) has a three hundred times higher affinity to MAO-A than B, whereas the bromopyrrole analog (7b) favours MAO-B eight times more than MAO-A. Improved activities with functional group modification were also notable in alypsinosins and bromopyrroles. It is clear that the current examples of MAOIs from marine natural products are not well understood, and require further research. Some of the examples have only early assay data or virtual experiments available, so discussion of their potential as good drug leads is contingent on further studies.

In conclusion, there are a small number of marine natural products that show MAO inhibitory activities. These inhibitors, with novel chemical structures, are potential leads for the further development of MAOI drugs from marine sources.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science and ICT under Grant No. NRF-2017R1D1A1B0302817 (to S.-J.N.), 2018R1A5A2025286 (to K.-M.L.).

ORCID

Le Cam Tu http://orcid.org/0000-0001-8271-8240
Inho Yang http://orcid.org/0000-0003-0990-1465
Sang-Jip Nam http://orcid.org/0000-0002-0944-6565

References

Al-Nuaimi SK, MacKenzie EM, Baker GB. 2012. Monoamine oxidase inhibitors and neuroprotection: a review. Am J Ther. 19(6):436–448.
Aoki S, Ye Y, Higuchi K, Takashima A, Tanaka Y, Kitagawa I, Kobayashi M. 2001. Novel neuronal nitric oxide synthase (nNOS) selective inhibitor, alypsinosin-type indole alkaloid, from marine sponge Hyrtios erecta. Chem Pharm Bull. 49(10):1372–1374.
Baird-Lambert J, Davis PA, Taylor KM. 1982. Methylaplysinopsin: a natural product of marine origin with effects on serotonin neurotransmission. Clin Exp Pharmacol Physiol. 9(2):203–212.
Bialonska D, Zjawiony JK. 2009. Aplysinopsins-marine indole alkaloids: chemistry, bioactivity and ecological significance. Mar Drugs. 7(2):166–183.
Bolasco A, Carradori S, Fioravanti R. 2010. Focusing on new monoamine oxidase inhibitors. Expert Opin Ther Pat. 20(7):909–939.
Cavalcante-Silva LHA, De Carvalho Correia AC, Barbosa-Filho JM, Da Silva BA, De Oliveira Santos BV, De Lira DP, Sousa JCF, De Miranda GEC, Cavalcante FA, Alexandre-Moreira MS. 2013. Spasmolytic effect of calepinine involves blockade of Ca2+ influx on guinea pig ileum. Mar Drugs. 11(5):1553–1564.
Connor JB, Polonsky J, Cohen P, Lederer E. 1963. Piloquinone: a new phenanthrene-O-quinone isolated from the mycelium of Streptomyces plicatus. Nature. 199:285–286.
Crne GE. 1956. The psychiatric side-effects of iproniazid. Am J Psychiatry. 112:494–497.
De Souza ET, De Lira DP, De Queiroz AC, Da Silva DJC, De Aquino AB, Campessato Mella EA, Lorenzo VP, De Miranda GEC, De Araújo-Júnior JX, De Oliveira Chaves MC, et al. 2009. The antinociceptive and anti-inflammatory activities of calepinin, a bisindole alkaloid isolated from the genus Caulerpa. Mar Drugs. 7(4):689–704.
Dezli L, Vecsei L. 2017. Monoamine oxidase B inhibitors in Parkinson’s disease. CNS Neurol Disord Drug Targets. 16(4):425–439.
Enterzorth M, Ratty AK. 2017. Monoamine oxidase inhibitors – revisiting a therapeutic principle. OJD. 06(02):31–68.
Erdogan Orhan I. 2016. Potential of natural products of herbal origin as monoamine oxidase inhibitors. Curr Pharm Des. 22(3):268–276.
Feng Y, Chu A, Luo Q, Wu M, Shi X, Chen Y. 2018. The protective effect of astaxanthin on cognitive function via inhibition of oxidative stress and inflammation in the brains of chronic T2DM rats. Front Pharmacol. 9:748–711.
Gaweska H, Fitzpatrick PF. 2011. Structures and mechanism of the monoamine oxidase family, Biomol Concepts. 2(5):365–377.
Hubáček P, Binda C, Khalil A, Li M, Mattevi A, Castagnoli N, Edmondson DE. 2005. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J Biol Chem. 280(16):15761–15766.
Jiang X, Zhu K, Xu Q, Wang G, Zhang J, Cao R, Ye J, Xu Y. 2017. The antidepressant-like effect of trans-astaxanthin involves the serotoninergic system. Oncotarget. 8(15):25552–25563.
Kazlauskas R, Murphy PT, Quinn RJ, Wells BJ, 1977. Aplysinopsin, a new tryptophan derivative from a sponge. Tetrahedron Lett. 18(1):61–64.

Figure 6. MAO inhibiting astaxanthin (9).
Kim H, Yang I, Patil RS, Kang S, Lee J, Choi H, Kim M-S, Nam S-J, Kang H. 2014. Anithiactins A-C, modified 2-phenylthiazoles from a mudflat-derived Streptomyces sp. J Nat Prod. 77(12):2716–2719.

Lee HW, Choi H, Nam S-J, Fenical W, Kim H. 2017. Potent inhibition of monoamine oxidase B by a piloquinone from marine-derived Streptomyces sp. CNQ-027. J Microbiol Biotechnol. 27(4):785–790.

Lee HW, Jung WK, Kim HJ, Jeong YS, Nam SJ, Kang H, Kim H. 2015. Inhibition of monoamine oxidase by anithiactins from Streptomyces sp. J Microbiol Biotechnol. 25(9):1425–1428.

Lee HW, Kim YJ, Nam SJ, Kim H. 2017. Potent selective inhibition of monoamine oxidase a by alternariol monomethyl ether isolated from Alternaria brassicae. J Microbiol Biotechnol. 27(2):316–320.

Lee I-K, Yun B-S, Oh S, Kim Y-H, Lee M-K, Yoo I-D. 1999. 5-Methylmellein and nectriapyrone, two new monoamine oxidase inhibitors. Med Sci Res. 27:463–465.

Lorenzo VP, Filho JMB, Scotti L, Scotti MT. 2015. Combined structure- and ligand-based virtual screening to evaluate caulerpin analogs with potential inhibitory activity against monoamine oxidase B. Braz J Pharmacogn. 25(6):690–697.

Rane R, Sahu N, Shah C, Karpoormath R. 2014. Marine bromopyrrole alkaloids: Synthesis and diverse medicinal applications. Curr Top Med Chem. 14(2):253–273.

Rane RA, Naphade S, Bangalore P. u, Sahu NU, Shah N, Kulkarni YA, Barve K, Lokare L, Karpoormath R. 2014. Synthesis and evaluation of novel marine bromopyrrole alkaloid-based derivatives as potential antidepressant agents. Chem Biol Drug Des. 84(5):593–602.

Safarova G, Safarov N, Gasanov R. 2016. Molecular docking of astaxanthin to monoamine oxidase. Adv Biol Earth Sci. 1:43–50.

Segraves NL, Crews P. 2005. Investigation of brominated tryptophan alkaloids from two thorectidae sponges: Thorectandra and Smenospongia. J Nat Prod. 68(10):1484–1488.

Shih JC, Chen K. 2004. Regulation of MAO-A and MAO-B gene expression. Curr Med Chem. 11(15):1995–2005.

Shih JC, Chen K, Ridd MJ. 1999. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci. 22:197–217.

Shulman KL, Herrmann N, Walker SE. 2013. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 27(10):789–797.

Son S-Y, Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T. 2008. Human monoamine oxidase A: structure and control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci USA. 105:5739–5744.

Takeuchi T, Ogawa K, Iinuma H, Suda H, Ukita K, Nagatsu T, Kato M, Umezawa H. 1973. Monoamine oxidase inhibitors isolated from fermented broths. J Antibiob. 26(3):162–167.

Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. 1985. Distinct monoamine oxidase A and B populations in primate brain. Science. 230(4722):181–183.